1. |
Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2007, 2(8): 706-714.
|
2. |
Mountain CF. Revisions in the international system for staging lung cancer. Chest, 1997, 111(6): 1710-1717.
|
3. |
Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am, 1987, 67(5): 1037-1049.
|
4. |
Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications. J Clin Oncol, 2000, 18(16): 2981-2989.
|
5. |
Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage ⅢA non-small-cell lung cancer. J Natl Cancer Inst, 1994, 86(9): 673-680.
|
6. |
Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med, 1994, 330(3): 153-158.
|
7. |
Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage ⅢA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg, 2003, 125(2): 254-260.
|
8. |
Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages Ⅲa and Ⅲb nonsmall cell lung cancer. A meta-analysis. Cancer, 1995, 76(4): 593-601.
|
9. |
Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 2010, 28(13): 2181-2190.
|
10. |
Elias AD, Kumar P, Herndon J, et al. Radiotherapy versus chemotherapy plus radiotherapy in surgically treated ⅢA N2 non-small-cell lung cancer. Clin Lung Cancer, 2002, 4(2): 95-103.
|
11. |
Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med, 1996, 125(9): 723-729.
|
12. |
Robinson LA, Ruckdeschel JC, Wagner H, et al. Treatment of non-small cell lung cancer-stage ⅢA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007, 132(3 Suppl): 243S-265S.
|
13. |
Lim E, Baldwin D, Beckles M, et al. Guidelines on the radical management of patients with lung cancer. Thorax, 2010, 65(Suppl 3): iii1-iii27.
|
14. |
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 2009, 6(7): e1000097.
|
15. |
Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007, 8: 16.
|
16. |
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
|
17. |
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
|
18. |
Kappers I, van Sandick JW, Burgers SA, et al. Surgery after induction chemotherapy in stage ⅢA-N2 non-small cell lung cancer: Why pneumonectomy should be avoided. Lung Cancer, 2010, 68(2): 222-227.
|
19. |
Koshy M, Fedewa SA, Malik R, et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage ⅢA(N2) non-small-cell lung cancer. J Thorac Oncol, 2013, 8(7): 915-922.
|
20. |
Aggarwal C, Li L, Borghaei H, et al. Multidisciplinary therapy of stage ⅢA non-small-cell lung cancer: Long-term outcome of chemoradiation with or without surgery. Cancer Control, 2014, 21(1): 57-62.
|
21. |
Darling GE, Li F, Patsios D, et al. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage ⅢA N2 non-small-cell lung cancer. Eur J Cardiothorac Surg, 2015, 48(5): 684-690.
|
22. |
Couñago F, Rodriguez de Dios N, Montemuiño S, et al. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage ⅢA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society). Lung Cancer, 2018, 118: 119-127.
|
23. |
Rajaram R, Correa AM, Xu T, et al. Locoregional control, overall survival, and disease-free survival in stage ⅢA (N2) non-small-cell lung cancer: Analysis of resected and unresected patients. Clin Lung Cancer, 2020, 21(4): e294-e301.
|
24. |
van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage ⅢA-N2 non-small-cell lung cancer. J Natl Cancer Inst, 2007, 99(6): 442-450.
|
25. |
Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage Ⅲ non-small-cell lung cancer: A phase Ⅲ randomised controlled trial. Lancet, 2009, 374(9687): 379-386.
|
26. |
Eberhardt WE, Pöttgen C, Gauler TC, et al. Phase Ⅲ study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage ⅢA(N2) and selected ⅢB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol, 2015, 33(35): 4194-4201.
|
27. |
Shah AA, Berry MF, Tzao C, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage ⅢA lung cancer. Ann Thorac Surg, 2012, 93(6): 1807-1812.
|
28. |
Tong S, Qin Z, Wan M, et al. Induction chemoradiotherapy versus induction chemotherapy for potentially resectable stage ⅢA (N2) non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Dis, 2018, 10(4): 2428-2436.
|
29. |
陈新林, 胡月, 郎建英, 等. RevMan、Stata 和 R 软件在生存资料 Meta 分析的应用. 中国循证医学杂志, 2016, 16(6): 736-740.
|
30. |
McGovern EM, Trastek VF, Pairolero PC, et al. Completion pneumonectomy: Indications, complications, and results. Ann Thorac Surg, 1988, 46(2): 141-146.
|
31. |
Beck N, Van Brakel TJ, Smit HJM, et al. Pneumonectomy for lung cancer treatment in the Netherlands: Between-hospital variation and outcomes. World J Surg, 2020, 44(1): 285-294.
|
32. |
Harmouchi H, Sani R, Belliraj L, et al. Pneumonectomy for non-tumoral diseases: Etiologies and follow-up in 38 cases. Asian Cardiovasc Thorac Ann, 2019, 27(4): 298-301.
|
33. |
Pricopi C, Mordant P, Rivera C, et al. Postoperative morbidity and mortality after pneumonectomy: A 30-year experience of 2064 consecutive patients. Interact Cardiovasc Thorac Surg, 2015, 20(3): 316-321.
|
34. |
Xu XL, Dan L, Chen W, et al. Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage ⅢA (N2) nonsmall-cell lung cancer: A meta-analysis and system review. Onco Targets Ther, 2016, 9: 845-853.
|
35. |
Hofmann HS, Braess J, Leipelt S, et al. Multimodality therapy in subclassified stage ⅢA-N2 non-small cell lung cancer patients according to the Robinson classification: Heterogeneity and management. J Thorac Dis, 2018, 10(6): 3585-3594.
|
36. |
Joosten PJM, Damhuis RAM, van Diessen JNA, et al. Results of neoadjuvant chemo(radio)therapy and resection for stage ⅢA non-small cell lung cancer in The Netherlands. Acta Oncol, 2020, 59(7): 748-752.
|
37. |
Girard N, Mornex F, Douillard JY, et al. Is neoadjuvant chemoradiotherapy a feasible strategy for stage ⅢA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase Ⅱ trial. Lung Cancer, 2010, 69(1): 86-93.
|
38. |
Barnett SA, Rusch VW, Zheng J, et al. Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: A review of 549 consecutive cases. J Thorac Oncol, 2011, 6(9): 1530-1536.
|
39. |
Inoue M, Sawabata N, Takeda S, et al. Results of surgical intervention for p-stage ⅢA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe. J Thorac Cardiovasc Surg, 2004, 127(4): 1100-1106.
|
40. |
Matsuguma H, Nakahara R, Ishikawa Y, et al. Postoperative radiotherapy for patients with completely resected pathological stage ⅢA-N2 non-small cell lung cancer: Focusing on an effect of the number of mediastinal lymph node stations involved. Interact Cardiovasc Thorac Surg, 2008, 7(4): 573-577.
|
41. |
Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage ⅢA lung cancer determines patient survival. Ann Thorac Surg, 2000, 70(6): 1826-1831.
|
42. |
de Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage Ⅲa lung cancer: Prediction of pathologic stage. J Thorac Oncol, 2010, 5(3): 389-398.
|
43. |
Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage Ⅲa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study. J Thorac Cardiovasc Surg, 2006, 131(6): 1229-1235.
|
44. |
De Waele M, Hendriks J, Lauwers P, et al. Restaging the mediastinum in non-small cell lung cancer after induction therapy: Non-invasive versus invasive procedures. Acta Chir Belg, May-Jun 2011, 111(3): 161-164.
|
45. |
Annema JT, Veseliç M, Versteegh MI, et al. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer, 2003, 42(3): 311-318.
|
46. |
De Waele M, Serra-Mitjans M, Hendriks J, et al. Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients. Eur J Cardiothorac Surg, 2008, 33(5): 824-828.
|